A CD14-targeting peptide delivered gene-silencing nanoparticles to inflammatory monocytes, reducing heart damage and fibrosis after heart attack in both mouse and pig models.
Validated in pig heart attack modelCD14-peptide-targeted siTET3 nanoparticles systemically administered to pigs after heart attack substantially reduced cardiac inflammation and improved outcomes
What the researchers found
Key findings across multiple models:
- TET3 expression in circulating monocytes was identified as an independent predictor of heart attack occurrence and patient prognosis in a clinical cohort
- A monocyte-targeting nanoparticle system was engineered using: periodic mesoporous silica loaded with siTET3, PEI/PEG coating, and a CD14 receptor-recognizing peptide (Cys-Gly-Trp-Arg-Arg-Arg-NH₂)
- In vitro: successfully reprogrammed inflammatory monocytes with attenuated pro-inflammatory phenotypes
- In mouse AMI model: markedly reduced infarct size and myocardial fibrosis
- In pig AMI model: substantial suppression of cardiac inflammation and improved post-infarction outcomes after systemic administration
Why it matters
Heart attacks remain a leading cause of death worldwide, and current treatments focus on restoring blood flow but do little to prevent the inflammatory damage that follows. This targeted approach addresses the inflammatory component by specifically reprogramming the immune cells that cause post-heart attack damage. The validation in a large animal (pig) model makes this particularly promising for clinical translation.
How the study worked
The study combined clinical data analysis (TET3 as predictor), nanoparticle engineering (PMS loaded with siTET3, surface-modified with PEI, PEG, and CD14-targeting peptide), in vitro monocyte reprogramming assays, in vivo mouse AMI models, and translational validation in a porcine (pig) AMI model with systemic administration.
What this study cannot tell us
While validated in both mouse and pig models, human clinical trials are needed. The CD14-targeting peptide could also affect other CD14-expressing cells beyond monocytes. Long-term effects of TET3 silencing on immune function are unknown. Manufacturing scalability of the nanoparticle system for clinical use was not addressed. The clinical cohort data identified TET3 as a predictor, but causation needs further confirmation.
How to read the evidence
This is a preclinical study with clinical biomarker discovery, in vitro validation, mouse model data, and large animal (pig) translational validation — representing a strong preclinical evidence package. However, no human therapeutic trials have been conducted.
When this study was published
Published in 2025, this is cutting-edge research at the intersection of peptide targeting, nanomedicine, and cardiovascular immunology.
The bigger picture
Targeted immunomodulation is an emerging frontier in cardiovascular medicine. While most heart attack treatments focus on restoring blood flow and preventing clots, addressing the inflammatory cascade that causes additional damage could significantly improve outcomes. This peptide-targeted approach demonstrates that selective immune cell reprogramming is feasible and effective, representing a potential paradigm shift in post-heart attack care.
Questions still open
- How long does the TET3 silencing effect last, and would repeated dosing be needed?
- Could this monocyte-targeting platform deliver other therapeutic genes for different cardiovascular conditions?
- What is the safety profile of systemic administration of these peptide-targeted nanoparticles in terms of immune suppression?
Common questions
How does the targeting peptide work in this therapy?
Why target monocytes after a heart attack?
Read the original research
Peptide-functionalized periodic mesoporous silica nanoparticles for monocyte-specific TET3 Silencing enhance cardiac repair after acute myocardial infarction.
Journal of nanobiotechnology, 23(1), 743
Citation
Jin, Hao; Ding, Jiandong; Zhang, Xiaoguo; Cheng, Shouquan; Zhang, Yahao; Wu, Yong; Liu, Cihui; Yang, Sirui; Zhang, Anjian; Ma, Genshan; Lu, Wenbin. (2025). Peptide-functionalized periodic mesoporous silica nanoparticles for monocyte-specific TET3 Silencing enhance cardiac repair after acute myocardial infarction.. Journal of nanobiotechnology, 23(1), 743. https://doi.org/10.1186/s12951-025-03782-4